Patents by Inventor Chensu WANG

Chensu WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination immunotherapy for treatment of melanoma, colon or non-small cell lung cancers
    Patent number: 12295986
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: May 13, 2025
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Chensu Wang, Karl Dane Wittrup, Darrell J. Irvine
  • COMBINATION IMMUNOTHERAPY DOSING REGIMEN FOR IMMUNE CHECKPOINT BLOCKADE
    Publication number: 20220096601
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Application
    Filed: December 2, 2021
    Publication date: March 31, 2022
    Inventors: Chensu Wang, Karl Dane Wittrup, Darrell J. Irvine
  • Combination immunotherapy dosing regimen for immune checkpoint blockade
    Patent number: 11235032
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: February 1, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Chensu Wang, Karl Dane Wittrup, Darrell J. Irvine
  • NOVEL TFEB PATHWAY AGONISTS FOR METABOLIC DISEASES AND AGEING
    Publication number: 20200333357
    Abstract: The present disclosure is directed to a nanotechnology-enabled screening strategy to identify small molecule TFEB agonists that shift maturation of autophagosomes to degradative autolysosomes.
    Type: Application
    Filed: November 13, 2018
    Publication date: October 22, 2020
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jinming GAO, Michael A. WHITE, Chensu WANG, Yang LI, Bruce POSNER, Gang HUANG
  • COMBINATION IMMUNOTHERAPY DOSING REGIMEN FOR IMMUNE CHECKPOINT BLOCKADE
    Publication number: 20200230208
    Abstract: The present disclosure provides a method of treating cancer with a priming dose of combination immunotherapy comprising IL-2 (e.g., extended-PK IL-2), an immune checkpoint inhibitor, a tumor targeting antibody or integrin-binding polypeptide, and optional cancer vaccine, administered prior to maintenance doses of immune checkpoint inhibitor therapy. The methods of the disclosure can be used to treat a broad range of cancer types.
    Type: Application
    Filed: November 22, 2019
    Publication date: July 23, 2020
    Inventors: Chensu WANG, Karl Dane WITTRUP, Darrell J. IRVINE